A cell therapy is under development for progressive multiple sclerosis (MS) patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.
Grit Biotechnology's GT201, a genetically engineered tumor-infiltrating lymphocyte (TIL) therapy, has been cleared by the FDA for clinical trials in advanced solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.